NCT06895187Not yet recruiting
Catheter Ablation Using a Novel Navigation and Imaging System
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The objective of the ENVIsIoN study is to collect data on the use of the VERAFEYE navigation and imaging system in patients indicated to undergo a catheter ablation procedure for the treatment of Paroxysmal Atrial Fibrillation (PAF).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 24 Mar 2025
- Start date
- 1 Mar 2027
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- LUMA Vision Ltd.
- Diseases
- Atrial fibrillation
- NCT number
- NCT06895187
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Mar 2027 to the primary completion date, 1 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Subject is 18 years of age at the time of consent, or of legal age to give informed consent specific to state and national law
- Subjects is eligible for a catheter ablation procedure with the VERAFEYE System as navigation and imaging system in the treatment of PAF (according to VERAFEYE System IFUs, current international and local guidelines and per physician discretion)
- Subject is able to understand and willing to provide written informed consent
- Subject is able to and willing to complete all study assessments associated with this clinical study at an approved clinical investigational center
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.